Literature DB >> 6325478

Identification of a laminin-like substance on the surface of high-malignant murine fibrosarcoma cells.

J P McCoy, R V Lloyd, M S Wicha, J Varani.   

Abstract

High- and low-malignant murine fibrosarcoma cells were stained with anti-laminin antibodies using immunoperoxidase techniques and examined by electron microscopy. With the high-malignant cells, specific staining was observed along the cell surface. Use of normal rabbit serum in place of the rabbit anti-laminin or pretreatment of the anti-laminin with soluble laminin completely eliminated this staining. No immunoperoxidase staining was observed with the low-malignant cells. In additional studies, membrane fractions were prepared from the high- and low-malignant cells and used to immunize rabbits. The animals immunized with the membrane fractions from the high-malignant cells produced antibodies that reacted by enzyme-linked immunosorbent assay (ELISA) with murine laminin obtained from the EHS sarcoma. The animals immunized with membrane fractions from the low-malignant cells did not. These studies provide strong evidence that the high-malignant cells (but not the low) express on their cell surface a substance that is immunologically cross-reactive with laminin. In addition, the high-malignant cells (but not the low) secreted a material into the cell culture fluid that could be specifically immunoprecipitated with antilaminin antibodies. The immunoprecipitated material co-migrated with purified laminin when examined by sodium dodecyl sulphate/polyacrylamide gel electrophoresis under reducing conditions. The existence of this substance associated with the surface of the high-malignant cells and its absence from that of the low-malignant cells may explain the previously noted difference between these cells in their ability to attach to type IV collagen. This difference may also contribute to the dissimilarity between these cells in their metastatic potential.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6325478     DOI: 10.1242/jcs.65.1.139

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  7 in total

Review 1.  Investigation of the antimetastatic effects of agents that inhibit cell adhesion or protein glycosylation.

Authors:  M J Humphries; K Matsumoto; S L White; K Olden
Journal:  J Natl Med Assoc       Date:  1987-04       Impact factor: 1.798

2.  Attachment, spreading and growth in vitro of highly malignant and low malignant murine fibrosarcoma cells.

Authors:  J Varani; I A Grimstad; R N Knibbs; T Hovig; J P McCoy
Journal:  Clin Exp Metastasis       Date:  1985 Jan-Mar       Impact factor: 5.150

3.  Laminin production by murine melanoma cells: possible involvement in cell motility.

Authors:  S E Fligiel; K A Laybourn; B P Peters; R W Ruddon; J C Hiserodt; J Varani
Journal:  Clin Exp Metastasis       Date:  1986 Oct-Dec       Impact factor: 5.150

4.  Cell surface laminin-like substances and laminin-related carbohydrates of rat ascites hepatoma AH7974 and its variants with different lung-colonizing potential.

Authors:  T Kawaguchi; T Ono; H Wakabayashi; S Igarashi
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

5.  Monoclonal antibodies that recognize the trisaccharide epitope Gal alpha 1-3Gal beta 1-4GlcNAc present on Ehrlich tumor cell membrane glycoproteins.

Authors:  M Takagaki; R N Knibbs; J Roth; I J Goldstein
Journal:  Histochemistry       Date:  1993-08

6.  Laminin inhibits the recognition of tumor target cells by murine natural killer (NK) and natural cytotoxic (NC) lymphocytes.

Authors:  J C Hiserodt; K A Laybourn; J Varani
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

7.  Increased mRNA expression of a laminin-binding protein in human colon carcinoma: complete sequence of a full-length cDNA encoding the protein.

Authors:  H K Yow; J M Wong; H S Chen; C G Lee; S Davis; G D Steele; L B Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.